InvestorsHub Logo
Followers 10
Posts 504
Boards Moderated 0
Alias Born 04/20/2016

Re: None

Saturday, 11/10/2018 12:33:41 PM

Saturday, November 10, 2018 12:33:41 PM

Post# of 425961
MatinasBiopharma is anxiously awaiting the details of the Vascepa trial to be announced today. If the Vascepa trial details are positive, Matinas will be the beneficiary as its drug, MAT 9001, beat Vascepa in a head to head comparative trial, the results of which are posted on Matinas' website.

Matinas is hoping Vascepa creates a big market for omega drugs which it can later enter when its superior drug is approved.

LM
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News